TCTN1

TCTN1 functions both as a transition-zone scaffold required for ciliary integrity and as a cytoplasmic scaffold that organizes metabolic and cytoskeletal machinery to control cell behavior (PMID:41446745, PMID:39325960). In Chlamydomonas, full-length TCTN1 is indispensable for ciliogenesis and transition-zone localization: neither the conserved DUF1619 domain alone nor truncated variants rescue ciliary morphology in tctn1-null cells, and C-terminal deletion destabilizes the protein during ciliary disassembly, establishing that intact protein architecture, not a single isolated domain, underlies its scaffolding role (PMID:41446745). In melanoma, TCTN1 acts as a protein scaffold that promotes binding between HADHA and HADHB, the two subunits of the mitochondrial trifunctional protein, thereby activating fatty acid oxidation and downstream p38/MAPK signaling to drive epithelial-mesenchymal transition and stemness; this scaffolding is functionally interruptible by a HADHA/HADHB binding blocker (PMID:39325960). TCTN1 also co-localizes with vimentin and actin in vascular smooth muscle cells, where it acts upstream of cyclin-CDK complex formation and cytoskeletal organization, reversing G0/G1 arrest, vimentin suppression, and F-actin depolymerization (PMID:41369411). Consistent with a role in proliferative control, TCTN1 depletion arrests the cell cycle and triggers apoptosis across multiple cancer cell types (PMID:29042969, PMID:25737023, PMID:28123172). Its expression is transcriptionally controlled by CTCF binding the TCTN1 promoter (PMID:41369411) and post-transcriptionally repressed by miR-216a-5p and miR-1256 acting on its mRNA (PMID:31297133, PMID:30008857).

1. 2015 Medium

   Whether TCTN1 influences cancer cell proliferation was unknown; depletion experiments established it as a positive regulator of cell-cycle progression in glioma.

   Evidence Lentiviral shRNA knockdown in U251 and U87MG glioma cells with proliferation and cell-cycle assays

   PMID:25737023

   Open questions at the time

   • No molecular mechanism linking TCTN1 to cycle machinery
   • No rescue to confirm specificity
   • Restricted to glioma lines
2. 2017 Medium

   It was unclear whether the proliferative requirement for TCTN1 generalized and engaged apoptotic programs; knockdown in thyroid and colorectal cancer linked loss of TCTN1 to cell-cycle arrest and caspase-dependent apoptosis.

   Evidence RNAi knockdown in thyroid and colorectal cancer cell lines with flow cytometry and western blotting of cycle/apoptosis proteins

   PMID:28123172 PMID:29042969

   Open questions at the time

   • Arrest phase differs between contexts (S vs G2/M) without explanation
   • No pathway rescue
   • Upstream effector of TCTN1 unidentified
3. 2018 Medium

   How TCTN1 levels are set was unaddressed; two studies showed direct miRNA repression, defining a post-transcriptional control layer.

   Evidence Luciferase 3'-UTR reporter assays with miR-1256 (NSCLC) and miR-216a-5p (esophageal carcinoma), plus protein-level and rescue experiments

   PMID:30008857 PMID:31297133

   Open questions at the time

   • Endogenous physiological relevance of these miRNAs not established
   • No in vivo confirmation
4. 2021 Low

   The transcriptional drivers of TCTN1 were unknown; a promoter analysis implicated TFAP2A at the core promoter.

   Evidence Promoter reporter assay defining the core promoter in oral squamous cell carcinoma cells

   PMID:34859261

   Open questions at the time

   • Single method without ChIP or knockout validation
   • Direct binding not demonstrated
   • Limited mechanistic depth
5. 2025 High

   Whether TCTN1 had a defined molecular activity beyond a proliferation phenotype was open; reciprocal Co-IP and rescue established it as a scaffold promoting HADHA-HADHB assembly to activate fatty acid oxidation and p38/MAPK-driven EMT.

   Evidence Co-immunoprecipitation, molecular docking, knockdown/overexpression with in vitro and in vivo metastasis models, and small-molecule binding-blocker rescue in melanoma

   PMID:39325960

   Open questions at the time

   • Structural basis of the TCTN1-HADHA/HADHB interface not resolved
   • Whether scaffold function is melanoma-specific or general
   • Relationship between mitochondrial scaffolding and ciliary role unclear
6. 2025 High

   The structural requirements for TCTN1's ciliary function were undefined; systematic domain-deletion rescue showed full-length integrity, not the conserved DUF1619 domain alone, is required for ciliogenesis and transition-zone localization.

   Evidence Stable expression of full-length and four truncated constructs in Chlamydomonas tctn1-null cells with quantitative ciliary morphology, localization, and stability readouts

   PMID:41446745

   Open questions at the time

   • Identity of the partners stabilizing full-length TCTN1 at the transition zone not defined
   • Conservation of this requirement in mammalian cilia not tested
7. 2025 Medium

   Whether TCTN1 connects to cytoskeleton and cycle control in non-cancer cells was unknown; in vascular smooth muscle cells it was placed upstream of cyclin-CDK assembly and cytoskeletal organization, with CTCF identified as a transcriptional regulator.

   Evidence Comparative proteomics, overexpression rescue, cyclin-CDK Co-IP, immunofluorescence co-localization with vimentin/actin, and CTCF ChIP/knockout

   PMID:41369411

   Open questions at the time

   • Direct biochemical interaction of TCTN1 with vimentin/actin not demonstrated
   • Single-lab study
   • Mechanism linking TCTN1 to cyclin-CDK assembly unresolved

• How TCTN1's transition-zone scaffolding role mechanistically connects to its cytoplasmic metabolic and cytoskeletal scaffold functions in disease contexts remains unresolved.
• No unifying structural model of TCTN1 scaffolding
• Whether ciliary and mitochondrial functions share a common partner-binding surface unknown
• No human Mendelian disease linkage in the corpus